How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Mycobacterium Tuberculosis Nucleic Acid Detection Kit Market
- By Product Type: Real-Time PCR Kits, Isothermal Amplification Kits, DNA Microarray Kits, Multiplex PCR Kits, Line Probe Assay Kits
- By Sample Type: Sputum Samples, Blood Samples, Bronchoalveolar Lavage Fluid, Urine Samples, Tissue Biopsy Samples
- By End User: Hospitals, Diagnostic Laboratories, Research Institutes, Public Health Laboratories, Reference Laboratories
- By Technology: Polymerase Chain Reaction (PCR), Loop-Mediated Isothermal Amplification (LAMP), Nucleic Acid Hybridization, Microarray Technology
- By Application: Active Tuberculosis Diagnosis, Drug Resistance Detection, Latent Tuberculosis Infection Screening, Epidemiological Surveillance
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Real-Time PCR Kits leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 303 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.182 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.190 →
Full report · locked preview
Everything inside the Mycobacterium Tuberculosis Nucleic Acid Detection Kit Market report
A complete, evidence-based study - 12 chapters and 127 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Sample Type 5
End User 5
Technology 4
Application 4
Companies profiled
Hain Lifescience GmbH
Cepheid (a Danaher company)
Qiagen N.V.
Abbott Laboratories
F. Hoffmann-La Roche AG
Becton
Dickinson and Company (BD)
bioMérieux SA
Thermo Fisher Scientific Inc.
Luminex Corporation
Molbio Diagnostics Pvt. Ltd.
Nipro Corporation
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Hain Lifescience GmbH
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Cepheid (a Danaher company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Qiagen N.V.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →F. Hoffmann-La Roche AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Dickinson and Company (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →bioMérieux SA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Thermo Fisher Scientific Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Luminex Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Molbio Diagnostics Pvt. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Nipro Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Seegene Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Fast Track Diagnostics (a Siemens Healthineers company)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Bioneer Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Genomica S.A.U.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$12,406M by 2033 · 11.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Real-Time PCR Kits37.4
- Isothermal Amplification Kits16.9
- DNA Microarray Kits17.4
- Multiplex PCR Kits13.9
- Line Probe Assay Kits14.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,727M → $4,015M · 11.1%
Europe$1,204M → $2,708M · 10.7%
Asia Pacific$1,099M → $2,918M · 13.0%
Latin America$680.3M → $1,635M · 11.6%
Middle East and Africa$523.3M → $1,387M · 13.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.342026
11.352027
11.362028
11.372029
11.392030
11.402031
11.412032
11.422033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Hain Lifescience GmbH23.6
- Cepheid (a Danaher company)27.6
- Qiagen N.V.3.8
- Abbott Laboratories4.2
- F. Hoffmann-La Roche AG6.6
- Becton6.2
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type22.8%
Sample Type13.8%
End User17.7%
Technology25.5%
Application20.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.7
- Europe21.4
- Asia Pacific23.0
- Latin America12.9
- Middle East and Africa11.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Hain Lifescience GmbH | 79 | 96 | 92 | 83 | 83 | 73 | 84 |
| Cepheid (a Danaher company) | 78 | 68 | 87 | 87 | 93 | 88 | 84 |
| Qiagen N.V. | 70 | 67 | 82 | 83 | 77 | 67 | 74 |
| Abbott Laboratories | 60 | 60 | 82 | 76 | 72 | 63 | 69 |
| F. Hoffmann-La Roche AG | 63 | 75 | 65 | 66 | 56 | 52 | 63 |
| Becton | 59 | 55 | 53 | 70 | 66 | 56 | 60 |
| Dickinson and Company (BD) | 49 | 66 | 65 | 65 | 58 | 55 | 60 |
| bioMérieux SA | 41 | 38 | 59 | 55 | 45 | 42 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Hain Lifescience GmbH
- Cepheid (a Danaher company)
- Qiagen N.V.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Hain Lifescience GmbH | ✓ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Cepheid (a Danaher company) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Qiagen N.V. | ✓ | ◐ | ✓ | ✓ | ◐ | ◐ |
| Abbott Laboratories | − | ◐ | ✓ | ✓ | ◐ | ◐ |
| F. Hoffmann-La Roche AG | − | ✓ | ◐ | ◐ | ◐ | ◐ |
| Becton | − | − | ◐ | ◐ | ◐ | ◐ |
| Dickinson and Company (BD) | − | ◐ | − | ◐ | ◐ | − |
| bioMérieux SA | − | − | ◐ | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Hain Lifescience GmbH84
2Cepheid (a Danaher company)84
3Qiagen N.V.74
4Abbott Laboratories69
5F. Hoffmann-La Roche AG63
6Becton60
7Dickinson and Company (BD)60
8bioMérieux SA47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Hain Lifescience GmbHCepheid (a Danaher company)
Challenger2
Strong scale, closing on the leaders.
Qiagen N.V.Abbott Laboratories
Contender3
Focused players with pockets of strength.
F. Hoffmann-La Roche AGBectonDickinson and Company (BD)
Niche1
Specialists in a single segment or region.
bioMérieux SA
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across Mycobacterium Tuberculosis Nucleic Acid Detection Kit Market — a $87M beachhead inside a $1.18B market.
Beachhead (SOM)$87Mobtainable near-term
Serviceable (SAM)$478Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Real-Time PCR Kits
Best fit — highest urgency & budget in Product Type.
Economic buyer76 fit
Isothermal Amplification Kits
Strong fit — clear ROI and a fast path to value.
End user66 fit
DNA Microarray Kits
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Sample Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel29%
Digital / self-serve19%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Mycobacterium Tuberculosis Nucleic Acid Detection Kit Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified25%
Evaluation14%
Closed-won6%
$14.8KCAC
$68KLTV
4.6:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Mycobacterium Tuberculosis Nucleic Acid Detection Kit Market is a resilient opportunity — $4.43B by 2033, compounding at 3.8%.
TAM · 2025$3.28Btoday
TAM · 2033$4.43Bforecast
CAGR3.8%2027–2033
Cumulative$34.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.43BTotal addressable market
SAM$1.63BServiceable available market
SOM$285MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.8% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.43BLarge & growingTAM by 2033 at 3.8% CAGR
$1.63BServiceable nowreachable with today’s model
$285MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.46BBear2.5% CAGR
$4.43BBase3.8% CAGR
$5.67BBull5.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Sample Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Mycobacterium Tuberculosis Nucleic Acid Detection Kit Market — a $10.2B market by 2033. Plan: grow share from 5.8% to 12.0%.
Market size · 2033$10.2Btotal addressable
Market CAGR9.9%2027–2033
Target share12.0%from 5.8% today
Revenue ambition$1.23Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 5.8% | 12.0% | On track |
| Revenue | $580M | $1.23B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 35.4% | 44.6% | Ahead |
| Customer retention | 89.6% | 93.0% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Sample Type capability
A defensible second engine — invest in Sample Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Sample Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $180M capacity & capability investment
- Greenlight bolt-on M&A in Sample Type
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAt risk
- Input-cost & supply riskAhead
- Regulatory / policy changeAt risk
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Mycobacterium Tuberculosis Nucleic Acid Detection Kit Market conversation — a $1.16B market you can size, segment and defend in minutes.
Market size · 2033$1.16Btotal opportunity
Growth3.4%CAGR to 2033
Addressable buyers1,753+accounts in scope
Typical ROI6.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.9×return on cost, year one
< 3 mopayback period
$42K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Hain Lifescience GmbHCepheid (a Danaher company)Qiagen N.V.Abbott LaboratoriesF. Hoffmann-La Roche AGBectonDickinson and Company (BD)bioMérieux SA+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Mycobacterium Tuberculosis Nucleic Acid Detection Kit Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Mycobacterium Tuberculosis Nucleic Acid Detection Kit Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Mycobacterium Tuberculosis Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportMycobacterium Tuberculosis Detection Kits Market
Market size, share, segmentation and regional forecast.
$508M market · 2025 base year
View reportMycobacterium Tuberculosis Antibodies Market
Market size, share, segmentation and regional forecast.
$776M market · 2025 base year
View reportMycobacterium Infections Treatment Market
Market size, share, segmentation and regional forecast.
$647M market · 2025 base year
View reportMycobacterium Drug Sensitivity Detection Kit Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportMycobacterium Abscessus Treatment Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportMycobacteria Culture Tubes Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportMycalolide B Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportMyasthenia Gravis Treatment Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportMyasthenia Gravis (MG) Treatment Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportMyasthenia Gravis Diagnostic Reagents and Equipment Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportMute Nasal Dilators Market
Market size, share, segmentation and regional forecast.
$333M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.